Who we are
Celgene is a multinational biopharmaceutical company committed to improving the
lives of patients worldwide.
At Celgene, we seek to deliver truly innovative and life-changing drugs for our
patients. Our mission as a company is to build a major global biopharmaceutical
corporation while focusing on the discovery and the development of products
for the treatment of cancer and other severe, immune, inflammatory conditions.
There are numerous clinical trials at major medical centers using compounds from
Celgene. Investigational compounds are being studied for patients with incurable
hematological and solid tumour cancers, including multiple myeloma, myelodysplastic
syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), glioblastoma,
and ovarian, pancreatic and prostate cancer.
As committed as we are to clinical accomplishment, we are equally committed to patient
support, which is a guiding principle at Celgene. We believe all who can benefit
from our discoveries should have the opportunity to do so. Celgene puts patients
first with industry-leading programs that provide information, support and access
to our innovative therapies.